智翔金泰：GR1803注射液系统性红斑狼疮适应症获批临床试验

Core Viewpoint - Zhixiang Jintai (688443.SH) has received approval from the National Medical Products Administration for the clinical trial of its product GR1803 injection for systemic lupus erythematosus (SLE) [1] Group 1: Company Developments - The clinical trial application for GR1803 injection targeting SLE has been approved [1] - As of the announcement date, GR1803 injection is in the Phase II clinical trial stage for the indication of relapsed/refractory multiple myeloma [1] Group 2: Industry Context - There are currently two imported BCMA×CD3 targeted antibody drugs conditionally approved for marketing in China, but no products targeting SLE with the same mechanism have been launched [1]